Jane E. Remillard

Jane E. Remillard

Partner

Tel. 617.994.0774
Fax 617.742.4214
Email: jremillard@lahive.com

Background

Education

  • Princeton University, B.A., Molecular Biology, 1989
  • Boston University School of Law, J.D., 1993

Bar & Court Admissions

  • Massachusetts Bar
  • U.S. Patent and Trademark Office

Professional Involvement

  • American Bar Association
  • American Intellectual Property Law Association
  • Boston Patent Law Association
  • Massachusetts Bar Association
  • Women’s Bar Association

Honors & Awards

  • 2009 Honoree, Annual Boston University Law Women in Law Conference

    Massachusetts Super Lawyers® List 2009

    Massachusetts Super Lawyers® Rising Star List 2007

Practice Areas

Life Sciences, Medical Devices, Patents

Industry & Technical Focus

Biotechnology, Chemistry, Cellular and Molecular Biology, Immunology, Genomics, Gene Therapy, Biochemistry, Protein Chemistry

Practice Description

Ms. Remillard is chair of the Life Sciences group. She has 16 years of experience in worldwide patent counseling and strategic planning, including patent prosecution, freedom to operate evaluations, opinion work, public offerings, agreements, licensing, due diligence analyses, interferences, and oppositions involving a variety of biomedical technologies.

Jane represents a broad range of clients, from start-up biotechnology companies to established biopharmaceutical corporations, in developing and implementing effective IP strategies, building strong patent portfolios that protect and facilitate commercialization of products and assessing freedom to operate.  She is a leader in antibody patent prosecution and opinion work, representing some of the most significant companies in the field including: Medarex, Inc.; Amgen Inc.; Novartis; Genmab A/S; Hana Biosciences, Inc.; Inotek Pharmaceutical Corp; Merrimack Pharmaceuticals, Inc.; and Avant Therapeutics.

Jane also works with companies and investors to provide due diligence evaluations and opinions in connection with collaborations, acquisitions, licensing, and financing both in the U.S. and abroad. She has considerable experience with public offerings, including initial public offerings.

Notable Experience

  • Representing clients in initial public offerings (IPOs) and multi-million dollar deals, including Genmab A/S; Accentia Biopharmaceuticals, Inc.; Hana Biosciences, Inc.; and Medarex, Inc.
  • Advising investors, including venture capitalists and investment bankers, in assessing the strength of intellectual property assets held by prospective candidates for investment.
  • Prosecuting patent rights covering an antibody product, which constituted the IP for a $2 billion deal.
  • Organizing educational seminars with clients on antibody technologies for Examiners at the U.S. Patent and Trademark Office.

Publications & Speaking Engagements

  • Speaker, “On Antibodies…From Market Developments to Patent Protection,” for a group of European patent attorneys in Switzerland, February 2009.
  • Speaker, “Revisiting Restriction Practice: Weighing the Cost-Benefit of Making Restrictions Work in Favor of Your Patent Strategy,” American Conference Institute, February 2008.
  • Speaker, “Antibody Prosecution Strategies,” AIPLA Meeting, Washington, DC, 2007.
  • Speaker, “Antibody Prosecution Strategies,” American Conference Institute, Biotech Advanced Forum, November 2006.

Case studies

 
 
Our Thinking Expands Yours

The client, a group of venture capital investors, sought to invest in a small biotech discovery company that planned to commercialize a potentially profitable patent estate licensed from a prominent university » read more

News & Events

USPTO Pilot Program Accelerates the Patent Process for Small Entity Inventors » read more

PCT-Patent Prosecution Highway Pilot Program Begins January 29, 2010 » read more

Wyeth v. Kappos Is Final . . . What Now? » read more

March 20, 2010
Jeanne DiGiorgio and Maneesh Gulati present, "Patent Prosecution Strategies: Issues, Considerations and Solutions" » read more

Web Site Developed by  Neptune Web, Inc.